MedPath

FCN-411

Generic Name
FCN-411
Clinical Trials
Related News

Efficacy of Targeted Therapy Combined Chemotherapy in Advanced EGFR Positive NSCLC Patients

Not Applicable
Completed
Conditions
Non-small-lung-cell Cancer
NSCLC
EGFR Gene Mutation
Interventions
Drug: EGFR-TKI combined with chemotherapy (pemetrexed plus carboplatin)
First Posted Date
2020-09-17
Last Posted Date
2024-01-16
Lead Sponsor
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Target Recruit Count
114
Registration Number
NCT04552613
Locations
🇨🇳

China, Zhejiang, Hangzhou, Zhejiang, China

Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC

Recruiting
Conditions
Non-small Cell Lung Cancer
Interventions
Drug: Third-generation EGFR-TKI
First Posted Date
2020-03-27
Last Posted Date
2025-01-27
Lead Sponsor
Hunan Province Tumor Hospital
Target Recruit Count
800
Registration Number
NCT04324164
Locations
🇨🇳

Yongchang Zhang, Changsha, Hunan, China

Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC

Phase 2
Conditions
Respiratory Tract Diseases
Lung Diseases
Neoplasms
Non-Small-Cell Lung
Thoracic Neoplasms
Interventions
First Posted Date
2018-01-03
Last Posted Date
2018-01-03
Lead Sponsor
Sichuan Cancer Hospital and Research Institute
Target Recruit Count
144
Registration Number
NCT03389256
Locations
🇨🇳

Sichuan Provincial People's Hospital, Chengdu, Sichuan, China

🇨🇳

Sichuan Cancer Hospital, Chengdu, Sichuan, China

🇨🇳

West China Hospital, Sichuan University, Chengdu, Sichuan, China

EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism

Phase 2
Conditions
Nonsmall Cell Lung Cancer
EGFR Gene Mutation
Interventions
Drug: EGFR-TK Inhibitor
Drug: EGFR-TKI and Chemotherapy
First Posted Date
2016-12-26
Last Posted Date
2016-12-28
Lead Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Target Recruit Count
50
Registration Number
NCT03002844

EGFR-TKI With Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism

Phase 3
Conditions
Non-Small-Cell Lung Cancer
Interventions
Drug: Chemotherapy（pemetrexed/gemcitabine）
Drug: Chemotherapy（carboplatin）
First Posted Date
2016-08-08
Last Posted Date
2016-08-09
Lead Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Target Recruit Count
100
Registration Number
NCT02859077

A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy

Phase 2
Conditions
Lung Adenocarcinoma
EGFR Positive Non-small Cell Lung Cancer
Interventions
Radiation: Thoracic Hypofractionated Radiotherapy
First Posted Date
2016-06-02
Last Posted Date
2016-06-02
Lead Sponsor
First People's Hospital of Hangzhou
Target Recruit Count
76
Registration Number
NCT02788058

EGFR-TKI Concurrent With/Without WBRT in Brain Metastasis From NSCLC

Phase 3
Conditions
Non-Small Cell Lung Cancer
Interventions
Radiation: whole brain radiotherapy
First Posted Date
2016-03-21
Last Posted Date
2017-10-27
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
601
Registration Number
NCT02714010
Locations
🇨🇳

Sun Yat-sen University of cancer center, Guangzhou, Guangdong, China

Study of EGFR-TKI to Asymptomatic Brain Metastases of NSCLC

Phase 2
Conditions
Asymptomatic Brain Metastases of Non Small Cell Lung Cancer
Interventions
First Posted Date
2014-09-26
Last Posted Date
2014-09-26
Lead Sponsor
Wuhan Union Hospital, China
Target Recruit Count
70
Registration Number
NCT02250846

Efficacy Study of Chinese Medicine Plus EGFR-TKI Versus EGFR-TKI in Advanced Pulmonary Adenocarcinoma

Conditions
Cancer
Interventions
Drug: TCM
First Posted Date
2012-12-10
Last Posted Date
2016-07-13
Lead Sponsor
Shanghai University of Traditional Chinese Medicine
Target Recruit Count
470
Registration Number
NCT01745302
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy